{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:07:13Z","timestamp":1790197633516,"version":"4.1.0"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T00:00:00Z","timestamp":1679875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>This study obtained data on patients with cutaneous malignant melanoma (CMM) from the Surveillance, Epidemiology, and End Results (SEER) database, and used a deep learning and neural network (DeepSurv) model to predict the survival rate of patients with CMM and evaluate its effectiveness.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We collected information on patients with CMM between 2004 and 2015 from the SEER database. We then randomly divided the patients into training and testing cohorts at a 7:3 ratio. The likelihood that patients with CMM will survive was forecasted using the DeepSurv model, and its results were compared with those of the Cox proportional-hazards (CoxPH) model. The calibration curves, time-dependent area under the receiver operating characteristic curve (AUC), and concordance index (C-index) were used to assess the prediction abilities of the model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>This study comprised 37,758 patients with CMM: 26,430 in the training cohort and 11,329 in the testing cohort. The CoxPH model demonstrated that the survival of patients with CMM was significantly influenced by age, sex, marital status, summary stage, surgery, radiotherapy, chemotherapy, postoperative lymph node dissection, tumor size, and tumor extension. The C-index of the CoxPH model was 0.875. We also constructed the DeepSurv model using the data from the training cohort, and its C-index was 0.910. We examined how well the aforementioned two models predicted outcomes. The 1-, 3-, and 5-year AUCs were 0.928, 0.837, and 0.855, respectively, for the CoxPH model, and 0.971, 0.947, and 0.942 for the DeepSurv model. The DeepSurv model presented a greater predictive effect on patients with CMM, and its reliability was better than that of the CoxPH model according to both the AUC value and the calibration curve.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The DeepSurv model, which we developed based on the data of patients with CMM in the SEER database, was found to be more effective than the CoxPH model in predicting the survival time of patients with CMM.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2023.1165865","type":"journal-article","created":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T13:25:22Z","timestamp":1679923522000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Deep-learning-based survival prediction of patients with cutaneous malignant melanoma"],"prefix":"10.3389","volume":"10","author":[{"given":"Hai","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaohui","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xichun","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wai-kit","family":"Ming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfeng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liehua","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,27]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/S0025-6196(11)61033-1","article-title":"Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis","volume":"82","author":"Markovic","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.cps.2021.05.001","article-title":"Melanoma risk factors and prevention","volume":"48","author":"Dzwierzynski","year":"2021","journal-title":"Clin Plast Surg"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"202e","DOI":"10.1097\/PRS.0000000000004571","article-title":"Malignant Melanoma: Diagnostic and Management Update","volume":"142","author":"Knackstedt","year":"2018","journal-title":"Plast Reconstr Surg"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1615\/CritRevEukaryotGeneExpr.2020028454","article-title":"Malignant melanoma: skin cancer-diagnosis, prevention, and treatment","volume":"30","author":"Ahmed","year":"2020","journal-title":"Crit Rev Eukaryot Gene Expr"},{"key":"ref5","first-page":"1005","article-title":"Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification","volume":"28","author":"Rastrelli","year":"2014","journal-title":"In Vivo"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/CMR.0000000000000571","article-title":"Amelanotic melanoma","volume":"29","author":"Gong","year":"2019","journal-title":"Melanoma Res"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"500","DOI":"10.4065\/81.4.500","article-title":"Cutaneous malignant melanoma","volume":"81","author":"Cummins","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.hoc.2018.09.005","article-title":"Cutaneous melanoma-a review in detection, staging, and management","volume":"33","author":"Hartman","year":"2019","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1245\/s10434-018-6513-7","article-title":"Melanoma staging: American joint committee on cancer (AJCC) 8th edition and beyond","volume":"25","author":"Gershenwald","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jaad.2017.08.039","article-title":"Determination of the impact of melanoma surgical timing on survival using the National Cancer Database","volume":"78","author":"Conic","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1093\/jjco\/hyaa137","article-title":"Construction and validation of a prognostic nomogram for primary vulvar melanoma: a SEER population-based study","volume":"50","author":"Zhou","year":"2020","journal-title":"Jpn J Clin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.adaj.2017.01.019","article-title":"Determining the epidemiologic, outcome, and prognostic factors of oral malignant melanoma by using the surveillance, epidemiology, and end results database","volume":"148","author":"Lee","year":"2017","journal-title":"J Am Dent Assoc"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"4561","DOI":"10.1002\/cam4.3065","article-title":"Prognostic significance of tumor size for primary invasive cutaneous melanoma: a population-based study, 2004-2016","volume":"9","author":"Ma","year":"2020","journal-title":"Cancer Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"3054","DOI":"10.1016\/j.ejca.2009.05.009","article-title":"Meta-analysis of risk factors for cutaneous melanoma according to anatomical site and clinico-pathological variant","volume":"45","author":"Caini","year":"2009","journal-title":"Eur J Cancer"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1002\/hep.1840070628","article-title":"Multivariate survival analysis using Cox's regression model","volume":"7","author":"Christensen","year":"1987","journal-title":"Hepatology"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s10549-018-05097-5","article-title":"Re-interpretation of PAM50 gene expression as quantitative tumor dimensions shows utility for clinical trials: application to prognosis and response to paclitaxel in breast cancer","volume":"175","author":"Camp","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e12041","DOI":"10.1002\/trc2.12041","article-title":"Comparison of cox proportional hazards regression and generalized cox regression models applied in dementia risk prediction","volume":"6","author":"Goerdten","year":"2020","journal-title":"Alzheimers Dement (N Y)"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/pst.1630","article-title":"Assessing the prediction accuracy of cure in the cox proportional hazards cure model: an application to breast cancer data","volume":"13","author":"Asano","year":"2014","journal-title":"Pharm Stat"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12874-018-0482-1","article-title":"DeepSurv: personalized treatment recommender system using a cox proportional hazards deep neural network","volume":"18","author":"Katzman","year":"2018","journal-title":"BMC Med Res Methodol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/jebm.12373","article-title":"Brief introduction of medical database and data mining technology in big data era","volume":"13","author":"Yang","year":"2020","journal-title":"J Evid Based Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s40779-021-00338-z","article-title":"Data mining in clinical big data: the frequently used databases, steps, and methodological models","volume":"8","author":"Wu","year":"2021","journal-title":"Mil Med Res"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.3390\/cancers11091235","article-title":"Cancer diagnosis using deep learning: a bibliographic review","volume":"11","author":"Munir","year":"2019","journal-title":"Cancers (Basel)"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(18)31559-9","article-title":"Melanoma","volume":"392","author":"Schadendorf","year":"2018","journal-title":"Lancet"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1093\/annonc\/mdx176","article-title":"Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E\/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study","volume":"28","author":"Long","year":"2017","journal-title":"Ann Oncol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined Nivolumab and Ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)","volume":"390","author":"Schachter","year":"2017","journal-title":"Lancet"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.1245\/s10434-020-09341-5","article-title":"A novel Nomogram and risk classification system predicting the cancer-specific mortality of patients with initially diagnosed metastatic cutaneous melanoma","volume":"28","author":"Li","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12886-021-01968-6","article-title":"Development and validation of a nomogram to predict cancer-specific survival of uveal melanoma","volume":"21","author":"Zeng","year":"2021","journal-title":"BMC Ophthalmol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"8562","DOI":"10.1002\/cam4.3318","article-title":"Development and validation of prognostic nomogram in patients with nonmetastatic malignant melanoma: a SEER population-based study","volume":"9","author":"Xiao","year":"2020","journal-title":"Cancer Med"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s40257-019-00487-x","article-title":"Malignant melanoma of the vulva and vagina: a US population-based study of 1863 patients","volume":"21","author":"Wohlmuth","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41416-020-01144-5","article-title":"Understanding the impact of sex and stage differences on melanoma cancer patient survival: a SEER-based study","volume":"124","author":"Smith","year":"2021","journal-title":"Br J Cancer"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/S1470-2045(16)00072-3","article-title":"Nominal nomograms and marginal margins: what is the law of the line","volume":"17","author":"Randall","year":"2016","journal-title":"Lancet Oncol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s00405-022-07627-w","article-title":"A deep learning-based model predicts survival for patients with laryngeal squamous cell carcinoma: a large population-based study","volume":"280","author":"Liao","year":"2022","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"ref36","first-page":"324","article-title":"Artificial neural network analysis in preclinical breast cancer","volume":"15","author":"Motalleb","year":"2014","journal-title":"Cell J"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/S0140-6736(19)32998-8","article-title":"Deep learning for prediction of colorectal cancer outcome: a discovery and validation study","volume":"395","author":"Skrede","year":"2020","journal-title":"Lancet"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s12885-022-09217-9","article-title":"Deep-learning model for predicting the survival of rectal adenocarcinoma patients based on a surveillance, epidemiology, and end results analysis","volume":"22","author":"Yu","year":"2022","journal-title":"BMC Cancer"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"e205842","DOI":"10.1001\/jamanetworkopen.2020.5842","article-title":"Development and validation of a deep learning model for non-small cell lung cancer survival","volume":"3","author":"She","year":"2020","journal-title":"JAMA Netw Open"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/5745304","article-title":"Deep-learning-based survival prediction of patients in coronary care units","volume":"2021","author":"Yang","year":"2021","journal-title":"Comput Math Methods Med"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1165865\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T13:25:25Z","timestamp":1679923525000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1165865\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,27]]},"references-count":40,"alternative-id":["10.3389\/fmed.2023.1165865"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1165865","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,27]]},"article-number":"1165865"}}